PDS Biotechnology: Streamlined Phase 3 Design and Improved Financials Accelerate Path to Potential Approval

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on PDS Biotechnology, with a price target of $15.00.

Joseph Pantginis has given his Buy rating due to a combination of factors tied to both clinical and financial progress at PDS Biotechnology. He views the FDA’s acceptance of the amended Phase 3 VERSATILE-003 design, which elevates progression-free survival to an interim primary endpoint and keeps median overall survival for full approval, as significantly improving the visibility and timing of potential regulatory milestones.

He also highlights that the reduced sample size, while preserving statistical power, should shorten the trial duration to an expected interim PFS readout in roughly 1.5 years and help constrain cash burn. Combined with better-than-expected 2025 EPS results and the company’s ability to build on strong Phase 2 PFS data versus Keytruda monotherapy, he believes PDS Biotech now has a clearer, faster route to potential accelerated approval, supporting his positive stance on the shares.